Ixchel Loses 9th Circ. Appeal In Antitrust Row With Biogen
Law360 (September 17, 2020, 9:21 PM EDT) -- The Ninth Circuit on Thursday held that a lower court did not err in dismissing claims from Ixchel Pharma LLC that Biogen Inc. illegally undermined its development of a neuromuscular disease treatment by signing an anti-competitive deal with another company, affirming there was no tortious interference in the contract.
In the unpublished three-page opinion, the panel said it reached its decision following the California Supreme Court answering two of its certified questions on the case.
Among the answers that the high court gave in August is that a "rule of reason applies to determine the validity of a contractual provision by...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!